Compare CLH & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLH | BMRN |
|---|---|---|
| Founded | 1980 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1B | 10.0B |
| IPO Year | 1994 | 1999 |
| Metric | CLH | BMRN |
|---|---|---|
| Price | $288.95 | $58.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 17 |
| Target Price | ★ $290.82 | $87.24 |
| AVG Volume (30 Days) | 532.8K | ★ 2.1M |
| Earning Date | 05-21-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 7.28 | 1.80 |
| Revenue | ★ $2,944,978,000.00 | $1,313,646,000.00 |
| Revenue This Year | $4.18 | $13.34 |
| Revenue Next Year | $4.49 | $11.42 |
| P/E Ratio | $39.86 | ★ $32.80 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $178.29 | $50.76 |
| 52 Week High | $298.12 | $73.18 |
| Indicator | CLH | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 59.75 | 42.57 |
| Support Level | $225.18 | $56.08 |
| Resistance Level | $298.12 | $60.52 |
| Average True Range (ATR) | 7.42 | 2.25 |
| MACD | -1.28 | -0.41 |
| Stochastic Oscillator | 53.16 | 1.80 |
Clean Harbors Inc is an environmental and industrial services provider that provides parts cleaning and related environmental services to commercial, industrial, and automotive customers. Its business segments are Environmental Services and Safety-Kleen Sustainability Solutions. Environmental Services includes waste collection, transportation, treatment, recycling, and disposal, along with industrial maintenance services. Safety-Kleen Sustainability Solutions provides used oil collection and manufactures base oil, vacuum gas oil, and lubricants. The company generates the majority of its revenues from the Environmental Services segment and operates in the United States, with maximum revenue, and Canada.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.